Two challenging cases pose treatment questions

Wood, William
February 2011
Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p16
The article discusses two challenging cases that pose treatment questions regarding the use of several drugs like rituximab for patients who are suffering from chronic myelomonocytic leukemia (CML).


Related Articles

  • Rituximab.  // Reactions Weekly;Apr2015, Vol. 1547 Issue 1, p239 

    The article presents a case study of two patients who experienced grade 3 or grade 2 cytokinic reaction after administration of rituximab to treat hairy cell leukaemia.

  • New combination therapy improved OS in patients with CLL. Cona, Christen; Harris, Jason; Southall, Jennifer // Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p27 

    The article discusses research being done on the effectiveness of combining rituximab, fludarabine and cyclophosphamide for prolonging the lives of chronic lymphocytic leukemia patients, which references a study by Peter Hillmen and colleagues in a 2010 issue of the journal "Lancet."

  • Chemoimmunotherapy extended OS, PFS in patients with CLL.  // Hem/Onc Today;3/25/2011, Vol. 12 Issue 6, p33 

    The article reports that fludarabine with rituximab extended progression-free survival (PFS) and overall survival (OS) in chronic lymphocytic leukemia patients after long-term follow-up, which is based on a study conducted by J. A. Woyach and colleagues.

  • Rituximab: A Review of its Use in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia. Plosker, Greg L.; Figgitt, David P. // Drugs;2003, Vol. 63 Issue 8, p803 

    Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukaemia (CLL). While the optimal use of the drug in many...

  • Bendamustine/rituximab.  // Reactions Weekly;Dec2014, Vol. 1532 Issue 1, p51 

    The article presents a case report of a patient who developed severe neutropenia after receiving bendamustine and rituximab for treatment of chronic lymphocytic leukaemia.

  • Idelalisib + rituximab cost effective in CLL in Portugal.  // PharmacoEconomics & Outcomes News;Jul2015, Vol. 732 Issue 1, p20 

    The article reports on a study which found that idelalisib combined with rituximab is cost effective in the treatment of patients with relapsed/ refractory chronic lymphocytic leukaemia (CLL).

  • Idelalisib + rituximab good value for relapsed/refractory CLL.  // PharmacoEconomics & Outcomes News;Feb2016, Vol. 745 Issue 1, p17 

    The article discusses a study presented at the 57th Annual Meeting and Exposition of the American Society of Hematology in 2016 which shows that idelalisib in combination with rituximab (IR) when offered in patients with refractory chronic lymphocytic leukaemia (CLL) appears to be cost effective.

  • Rituximab responsive multiple radiculopathies and cranial nerve palsies in association with chronic lymphocytic leukaemia. Morrow, Jasper; D'Sa, Shirley; Page, Rupert; Hilali, Mahir; Lunn, Michael; Reilly, Mary // Journal of Neurology;Mar2012, Vol. 259 Issue 3, p571 

    The article discusses the potential of rituximab in treating multiple radiculopathies and cranial nerve palsies in association with chronic lymphocytic leukaemia (CLL). It cites the case of a 53-year-old woman with progressive multifocal neurological syndrome and developed patchy numbness and...

  • Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Castro, J. E.; Sandoval-Sus, J. D.; Bole, J.; Rassenti, L.; Kipps, T. J. // Leukemia (08876924);Nov2008, Vol. 22 Issue 11, p2048 

    We examined the clinical response of fludarabine-refractory CLL patients treated with high-dose methylprednisolone (HDMP) and rituximab. Fourteen patients were treated with three cycles of rituximab (375 mg/m(2) weekly for 4 weeks) in combination with HDMP (1 gm/m(2) daily for 5 days). All...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics